ArticleMolecular biology reports2025
Metabolic syndrome and effect of gene polymorphisms: ADIPOQ, AGT, AGTR1, AGTR2, ApoC-III, NR3C1 and GNB3 gene polymorphisms.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidating Genetic Drivers of Chronic Inflammation in Obesity.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MetS) is defined as a metabolic dysfunction characterized by the co-occurrence of multiple risk factors. Our study aimed to elucidate the effects of ADIPOQ rs266729, rs17300539, and rs2241766, AGT rs699 and rs4762, AGTR1 rs5186, AGTR2 rs11091046, ApoC-III rs2854116 and rs2854117, NR3C1 rs10052957 and rs41423247, and GNB3 rs5443 gene polymorphisms on MetS. METHODS AND
resultsA total of 200 patients who met the diagnostic criteria for MetS at the Internal Medicine Outpatient Clinic of Istanbul University, Faculty of Medicine, between 01.08.2022 and 20.05.2023, and 100 healthy controls were included in our study. ADIPOQ rs17300539 GA, AGT rs699 TT, AGTR1 rs5186 AC, and AGTR2 rs11091046 CC genotypes were more frequently observed in patients diagnosed with MetS compared to healthy controls (p < 0.05 for all). MetS patients with AGT rs699 TT genotype had a higher incidence of hypertension compared to individuals with CC/CT genotype of the same polymorphism (p = 0.047). Individuals with ADIPOQ rs17300539 AA/AG and NR3C1 rs41423247 CC genotypes were found to have higher mean waist circumferences compared to others (p < 0.05 for all). Individuals with ADIPOQ rs17300539 AA/AG, NR3C1 rs10052957 GG, and AGT rs4762 GA/AA genotypes exhibited significantly higher incidence of nephropathy. Individuals with ADIPOQ rs17300539 AA/AG and NR3C1 rs10052957 GG genotypes had a significantly higher incidence of retinopathy compared to others.
conclusionsThe study demonstrated that the ADIPOQ rs17300539, AGT rs699, AGTR1 rs5186, and AGTR2 rs11091046 polymorphisms are associated with an increased susceptibility to MetS. Significant results concerning clinical features and complications were also observed. Further research is necessary to elucidate the relationship between susceptibility to MetS, clinical and laboratory characteristics, and epigenetic modifications.
Indexed as
Identifiers
40272664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.